ADMA Biologics (NASDAQ:ADMA) Earns Sell Rating from Analysts at StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of ADMA Biologics (NASDAQ:ADMA – Get Rating) in a research note issued on Thursday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Separately, HC Wainwright restated a “buy” rating and issued a $4.50 price target on shares of ADMA Biologics in a research note on Wednesday, February 8th.

ADMA Biologics Trading Down 2.8 %

ADMA opened at $3.13 on Thursday. The company’s 50 day moving average is $3.51 and its 200-day moving average is $3.17. ADMA Biologics has a 1-year low of $1.43 and a 1-year high of $3.98. The company has a current ratio of 5.04, a quick ratio of 1.38 and a debt-to-equity ratio of 1.51. The company has a market cap of $615.92 million, a P/E ratio of -8.46 and a beta of 0.87.

Institutional Investors Weigh In On ADMA Biologics

Hedge funds have recently added to or reduced their stakes in the business. Viewpoint Capital Management LLC acquired a new stake in ADMA Biologics during the 2nd quarter worth approximately $26,000. Virtu Financial LLC acquired a new position in shares of ADMA Biologics in the 2nd quarter worth approximately $34,000. Price T Rowe Associates Inc. MD acquired a new position in shares of ADMA Biologics in the 2nd quarter worth approximately $35,000. Robeco Institutional Asset Management B.V. acquired a new position in shares of ADMA Biologics in the 4th quarter worth approximately $42,000. Finally, Metropolitan Life Insurance Co NY lifted its position in shares of ADMA Biologics by 61.5% in the 4th quarter. Metropolitan Life Insurance Co NY now owns 11,565 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 4,403 shares during the period. 71.17% of the stock is currently owned by institutional investors and hedge funds.

ADMA Biologics Company Profile

(Get Rating)

ADMA Biologics, Inc operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations.